<DOC>
	<DOCNO>NCT01516944</DOCNO>
	<brief_summary>Stage I：Neoadjuvant therapy - Tegafur，Gimeracil Oteracil Potassium Capsules plus oxaliplatin superior surgery alone ; Capecitabine plus oxaliplatin non-inferiority Tegafur，Gimeracil Oteracil Potassium Capsules plus oxaliplatin Stage II : Perioperative therapy - Perioperative Tegafur，Gimeracil Oteracil Potassium Capsules plus oxaliplatin superior adjuvant Tegafur，Gimeracil Oteracil Potassium Capsules plus oxaliplatin alone ; Capecitabine plus oxaliplatin regimen noninferiority Tegafur , Gimeracil Oteracil Potassium Capsules plus oxaliplatin - A regimen Tegafur，Gimeracil Oteracil Potassium Capsules plus oxaliplatin ( SOX ) Capecitabine plus oxaliplatin ( XELOX ) improve survival among patient incurable locally advanced metastatic gastric cancer . The investigator assess whether addition perioperative regimen SOX XELOX regimen adjuvant alone improves R0 resection rate survival among patient curable locally advanced gastric cancer .</brief_summary>
	<brief_title>Perioperative Chemotherapy Potentially Resectable Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age 18 75 Histologically cytologically proven operable advanced gastric adenocarcinoma ( include adenocarcinoma gastrooesophageal junction ) ECOG performance status ≦2 Tumor stage T3/4NxM0 No distant metastasis ( M0 ) History hypersensitivity fluoropyrimidines , Tegafur，Gimeracil Oteracil Potassium Capsules , capecitabine , oxaliplatin ingredient product Inadequate hematopoietic function： WBC≦4,000/mm3 ; ANC≦2,000/mm3 ; Platelet≦100,000/mm3 Inadequate organ function define : Total bilirubin &gt; 2 pper limit normal range ( ULN ) ; ALT / AST &gt; 2.5 upper limit normal range ( ULN ) ( &gt; 5.0 x ULN hepatic metastasis ) ; serum creatinine &gt; 1.2 mg/dL , Ccr &gt; 60 ml/min ( estimate CockcroftGault formulation ) ; Symptomatic peripheral neuropathy Receiving concomitant treatment fluoropyrimidines Pregnancy lactation woman , woman suspect pregnancy men unless use reliable appropriate contraceptive method . Mental status fit chemotherapy therapy presence serious concomitant illness might aggravate study medication : Active cardiac disease e.g . decompensate myocardial infarction within 6month period precede entry study . History ventricular arrhythmia congestive heart failure . Significant comorbid medical condition , include , limited , Chronic obstructive pulmonary disease , interstitial pneumonia , pulmonary fibrosis , heart failure , renal failure , hepatic failure , haemorrhagic peptic ulcer , mechanical paralytic ileus , poorly control diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Tegafur，Gimeracil Oteracil Potassium Capsules</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>perioperative Chemotherapy</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>